Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.

The new monthly price of $499, down from $650, takes effect immediately. Novo said the new pricing is available to both the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...